I'll ask you again. How do you explain Dr. Fareed's (and his colleagues, for that matter) great success using HCQ+ within five days of symptom onset in vulnerable-age patients?
I await your answer.
I'll ask you again. How do you explain Dr. Fareed's (and his colleagues, for that matter) great success using HCQ+ within five days of symptom onset in vulnerable-age patients?
I await your answer.